SCHEMBL550075

SCHEMBL550075

Clc1ccccc1-c1ccncc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.65
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C19 P33261 1/20 0.58
MAPK13 O15264 1/20 0.51
RAF1 P04049 1/20 0.51
MAPK12 P53778 1/20 0.51
MAPK11 Q15759 1/20 0.51
MAPK14 Q16539 1/20 0.51
NOTUM Q6P988 1/20 0.50
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 3/20 0.47
HSD17B10 Q99714 3/20 0.47
HTT P42858 2/20 0.47
HPGD P15428 2/20 0.47
APAF1 O14727 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3772831 0.82 P2RX7 (0.47) CYP2A6NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL4032281 0.82 NOTUM (0.63) NPC1RAB9ASMN1; SMN2MAPK14NOTUM
SCHEMBL30708901 0.82 NOTUM (0.63) NPC1RAB9ASMN1; SMN2MAPK14NOTUM
SCHEMBL5005152 0.80 NPC1 (0.45) CYP2A6NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL23628571 0.79 CYP2A6 (1.00) CYP2A6NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL12853983 0.79 NOTUM (0.60) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL1947212 0.79 NOTUM (0.60) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
Benzene SCHEMBL28342327 0.79 CYP2A6 (1.00) CYP2A6NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL29355088 0.79 CYP2A6 (1.00) CYP2A6NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL170230 0.79 CYP2A6 (1.00) CYP2A6NPC1RAB9ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4405792-A Substituted pyridines and their preparation ETHYL CORPORATION (US) 1983-09-20 US claimed
US-8110642-B2 Synthesis of vinylphenylpyridine and living anionic polymerization GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-02-07 US disclosed
US-20110077395-A1 INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I BRISTOL-MYERS SQUIBB COMPANY 2011-03-31 US disclosed
US-20110077395-A1 INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I BRISTOL-MYERS SQUIBB COMPANY 2011-03-31 US disclosed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
EP-1805142-A4 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS INC (US) 2009-06-10 EP disclosed
US-20090105416-A1 Synthesis of Vinylphenylpyridine and Living Anionic Polymerization GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-04-23 US disclosed
WO-2007129810-A1 SYNTHESIS OF VINYLPHENYLPYRIDINE AND LIVING ANIONIC POLYMERIZATION GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2007-11-15 WO disclosed
EP-1805142-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-07-11 EP disclosed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed
WO-2006034474-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO disclosed
US-4533735-A Process for preparing antibacterial compounds ETHYL CORPORATION (US) 1985-08-06 US disclosed
US-4490535-A 4-(3- and 4-Chlorocyclohex-3-enyl)pyridine intermediates ETHYL CORPORATION (US) 1984-12-25 US disclosed
US-4405792-A Substituted pyridines and their preparation ETHYL CORPORATION (US) 1983-09-20 US disclosed
US-4405792-A Substituted pyridines and their preparation ETHYL CORPORATION (US) 1983-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077395-A1 INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I HSD11B1, HSD3B1, HSD17B1 CYP2A6 249/4885NPC1 303/4885RAB9A 758/4885
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them LDLR, LRP6, PLPBP CYP2A6 3558/4885NPC1 1840/4885RAB9A 3129/4885
US-20090105416-A1 Synthesis of Vinylphenylpyridine and Living Anionic Polymerization PBRM1, MVD, PCBP1 CYP2A6 1144/4885NPC1 4810/4885RAB9A 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.